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A B S T R A C T
In the present study, we prepared nattokinase-loaded self-double-emulsifying drug deliv-
ery system (SDEDDS) and investigated its preliminary pharmacodynamics. The type and
concentration of oil phase, inner aqueous phase and emulsifier were screened to prepare
optimum nattokinase-loaded SDEDDS. Next, the optimum formulations were character-
ized based on microstructure, volume-weighted mean droplet size, self-emulsifying rate,
yield, storage stability, in vitro release and in vivo pharmacodynamics studies. The water/
oil/water multiple emulsions exhibited typical multiple structure, with relatively small volume-
weighted mean droplet size 6.0 ± 0.7 μm and high self-emulsifying ability (self-emulsifying
time <2 min). Encapsulation of nattokinase was up to 86.8 ± 8.2%. The cumulative release
of nattokinase within 8 h was about 30%, exhibiting a sustained release effect. The phar-
macodynamics study indicated that nattokinase-loaded SDEDDS could significantly prolong
the whole blood clotting time in mouse and effectively improve the carrageenan-induced
tail thrombosis compared with nattokinase solution. Moreover, we showed that SDEDDS could
successfully self-emulsify into water/oil/water multiple emulsions upon dilution in disper-
sion medium with gentle stirring and effectively protect nattokinase activity in gastric
environment. Our findings suggested that SDEDDS could be a promising strategy for peptide
and protein drugs by oral administration.
© 2015 Production and hosting by Elsevier B.V. on behalf of Shenyang Pharmaceutical
University. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).
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1. Introduction
With the development of biotechnology, such as genetic en-
gineering, molecular biology and so on, the stability of peptide
and protein drugs has been prominently increased [1].
Nattokinase was firstly discovered by Sumi H et al. [2] in 1987.
Compared with other thrombolytic drugs (urokinase,
lumbrukinase and so on), nattokinase has many unique ad-
vantages, such as abundant sources, low cost, long half-life,
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low side effects and high fibrinolytic activity. Moreover,
nattokinase is also resistant to trypsin hydrolysis in intes-
tine, and it can be administered either intravenously or orally
[3,4], making it ideal for the prevention and treatment of em-
bolism. Studies have shown that nattokinase is orally effective,
and it can be absorbed in intestine [5–7]. The optimum pH for
fibrinolytic activity of Nattokinase was around 9 and the enzyme
activity decreased rapidly at level below pH 5 [2,8]. Enteric
coating is essential to protect the enzyme component of
nattokinase from gastric acid degradation, there are nattokinase
enteric-coated capsules [2], enteric-coated tablets [9] and other
health care products on the market. Recently, lipid-based new
drug delivery systems have shown great potential to further
improve the absorption of peptide and protein drugs [10,11].
Especially, the water/oil/water multiple emulsions have re-
ceived a great deal of attention [12–16]. So far, there have no
literature reports related to the nattokinase incorporated emul-
sions, included self-double-emulsifying drug delivery system
(SDEDDS).
SDEDDS is the mixture of water-in-oil emulsions and hy-
drophilic emulsifiers, which can self-emulsify into water/oil/
water multiple emulsions followed by dilution with aqueous
media under gastrointestinal motility or mild agitation at the
ambient temperature [17]. This type of drug delivery system
has significant advantages as follows. On one hand, SDEDDS
can avoid the inactivation and enzymatic degradation of peptide
and protein drugs in gastrointestinal tract. Meanwhile, the ab-
sorption and pharmacological activity of the drugs can be
significantly increased compare with other formulations [18–20].
On the one hand, SDEDDS can realize the spontaneous emul-
sification due to the gastrointestinal motility in vivo instead
of artificial emulsification in vitro[17].Therefore, SDEDDS is more
stable compared with conventional thermodynamically un-
stable multiple emulsions [12], and it can effectively avoid the
poor stability of multiple emulsions during preparation and
storage in vitro. Besides, SDEDDS greatly facilitates the pa-
tients by reducing the dose volume.
In the present study, we prepared nattokinase-loaded
SDEDDS. Firstly, the optimum SDEDDS formulations were ob-
tained by screening the type and concentration of the oil phase,
inner aqueous phase and emulsifier. Then, the microstruc-
ture, volume-weighted mean droplet size, self-emulsifying rate,
yield, storage stability, and nattokinase release from SDEDDS
were evaluated in vitro. Finally, KM mice were utilized as an
animal model for pharmacodynamics study in vivo.
2. Material and methods
2.1. Materials
Medium chain triglycerides (MCT) was purchased from Avia-
tion Pharmaceutical Co., Ltd. (Liaoning, China). Liquid paraffin
was purchased from Tianjin Kermel Chemical Reagent Co., Ltd.
(Tianjin, China). Sorbitane monooleate (Span80) was pur-
chased from Chengdu Kelong Chemical Reagent Factory
(Chengdu, China). Polyethylene glycol (30) dimer hydroxy stea-
rate (Arlacel P135) was purchased from Guangdong Peng
Chemical Co., Ltd. (Guangdong, China). Cetyl PEG/PPG-10/1
dimethicone (Abil®EM90) was purchased from Guangzhou Wei
Xi Chemical Co., Ltd. (Guangdong, China). Caprylocaproyl
Macrogolglycerides EP (Labrasol®)was a gift sample from
Gattefosse, France. Enhanced BCA protein Assay was pur-
chased from Beyotime (Jiangsu, China). Nattokinase was
purchased from National Enzyme Company (Beijing, China).
Carrageenan was purchased from Sigma (Beijing, China). Lab-
made ultra-pure water. All other chemicals were of analytical
grade.
Kunming mice, clean degree, weighting (20 ± 2) g, half males
and half females, were purchased from Experimental Animal
Center of Sichuan University (Chengdu, China). All animal ex-
periments were approved by the Animal Experimental Ethical
Committee of West China School of Pharmacy, Chengdu, China,
Animal production license numbers was SCXK (chuan) 2013-026.
2.2. Screening the composition and preparation condition
of SDEDDS formulations
Oil phase and lipophilic emulsifier were weighed at certain ratio
and then well mixed.The coarse water/oil emulsions were pre-
pared by slowly dropping the inner aqueous phase (water or
20 mg/mL nattokinase solution) into oil phase with magnetic
stirring (1000 rpm) at room temperature. Fine and homoge-
neous water/oil emulsions were obtained under different
homogenization condition (10000 rpm 3 min/6 min/9 min,
13000 rpm 3 min/6 min/9 min) (FJ-200 high-speed dispersion
homogenizer, Jiangsujintan Jincheng Instruments Co., Jiangsu,
China). Finally, nattokinase-loaded SDEDDS was obtained by
proportionally mixing the water/oil emulsions with Labrasol
under magnetic stirring.
The type of commonly used self-emulsifying oil phase (MCT
and liquid paraffin) and lipophilic emulsifiers (Abil EM90, Arlacel
P135 and Span80) was investigated through microscopic mor-
phology, volume-weighted mean droplet size and self-
emulsifying area. Concentrations of lipophilic emulsifier varying
from 10% to 25% (w/w), hydrophilic emulsifier varying from 10%
to 20% (w/w) and inner aqueous phase varying from 30% to
50% (w/w) were also screened to optimize SDEDDS formulations.
The particle size and microscopic morphology of SDEDDS
formulations after self-emulsifying into water/oil/water mul-
tiple emulsions were the index used for preparation
optimization. The microscopic morphology was studied under
inverted fluorescence microscope (×400, Axiovert 40CFL, Carl
Zeiss, Germany) and the particle size distribution was deter-
mined by dynamic light scattering (Mastersizer 2000, Malvern
Instruments Ltd., Worcestershire, UK) equipped with a He–
Ne laser (k = 623 nm), respectively. The results were recorded
as the typical volume-weighted mean droplet size D [3,4]. Each
formulation was carried out three times in parallel, and data
were presented as Mean ± SD. Pseudo-ternary phase dia-
grams were constructed with emulsifier titration method [18].
A series of mixtures consisting of water/oil emulsions and water
phase were accurately weighed into vials at certain ratios (0:10,
1:9, 2:8, 3:7, 4:6, 5:5, 6:4, 7:3, 8:2, 9:1, 10:0), and then they were
uniformly mixed under magnetic stirring at room tempera-
ture. Labrasol was then added into each mixture drop by drop.
Meanwhile, samples were stirred and observed through mi-
croscopy. The total mass of samples at which water/oil/water
multiple emulsions formed and disappeared under micro-
scopic observation was recorded as m1 and m2, respectively.
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These values were used to determine the boundaries of the
multiple emulsions regions, through which optimum ratios of
combination vehicles were selected to develop nattokinase-
loaded SDEDDS and calculate self-emulsifying area.
2.3. Characterization of SDEDDS formulations
2.3.1. Microstructure observation
The morphology of SDEDDS formulations after transforma-
tion into water/oil/water multiple emulsions was observed
respectively under inverted fluorescence microscope (×400,
Axiovert 40CFL, Carl Zeiss, Germany), upright fluorescence mi-
croscope with an optical immersion microscope (×1,000, Leica
DM1000, Germany), confocal laser scanning laser microscope
(×2,000, CSLM, Leica SP5, Germany, both inner and outer aqueous
phase containing 10 μg/ml sodium fluorescein) using an Ar/
Kr laser at an excitation of 491 nm, and transmission electron
microscope (×20,000, H–6001V, HITACHI, Japan).
2.3.2. Particle size analysis
The particle size distribution of SDEDDS formulations after
transformation into water/oil/water multiple emulsions was
determined by dynamic light scattering (Mastersizer 2000,
Malvern Instruments Ltd., Worcestershire, UK) equipped with
a He–Ne laser (k = 623 nm). The results were recorded as the
typical volume-weighted mean droplet size D [3,4]. Each for-
mulation was carried out three times in parallel, and data were
presented as Mean ± SD.
2.3.4. Determination of the self-emulsifying rate of SDEDDS
formulations
The turbidity method was used to determine the self-
emulsifying rate of SDEDDS formulations. Briefly, appropriate
amount of SDEDDS formulations was added into dissolution
vessels containing 200 ml outer aqueous phase at 37 ± 0.5 °C,
and the speed of the paddle was adjusted to 100 rpm. Samples
were withdrawn at different time intervals, and the absor-
bance at a wavelength of 330 nm was measured until
equilibrium was established. Absorbance A represented tur-
bidity, and the relative turbidity A ′ was calculated according
to the formula (1). Curves showing changes of turbidity and
relative turbidity with time were drawn.T90 (the time when tur-
bidity reached 90% of the maximum turbidity) represented
complete self-emulsifying time of SDEDDS formulations.
′ =
−
−
A
A A
A A
t min
max min
(1)
where A ′ is the relative turbidity, Amin is the minimum tur-
bidity value throughout the whole process,Amax is the maximum
turbidity value at equilibrium, and At is the turbidity value at
a given time t.
2.3.5. Investigation of yield and storage stability
Yield, also called encapsulation efficiency, is the most impor-
tant parameter characterizing the success of a multiple
emulsion preparation procedure [21], which can be defined as
the percentage of the aqueous phase marker added to the inner
aqueous phase which remains entrapped in the inner aqueous
phase on manufacture of the W/O/W multiple emulsions [22].
According to the above-mentioned method in section 2.1,
optimum blank and nattokinase-loaded SDEDDS formula-
tions (nattokinase was 20 mg/ml in inner aqueous phase)
were constructed. They could self-emulsify into water/oil/
water multiple emulsions under mild agitation followed by
dilution with outer aqueous phase. Briefly, 1 ml freshly
prepared water/oil/water multiple emulsions was diluted
with 14 ml purified water and centrifuged at 10,000 rpm for
15 min at 4 °C in a refrigerated centrifuge. The resulting
lower outer aqueous phase was collected into a 1 ml syringe
and filtered through a membrane filter (0.22-μm pore size) to
eliminate the oil droplets. Subsequently, it was analyzed by
Chemiluminescence Apparatus (Varioskan Flash, Thermo sci-
entific, USA) with the BCA kit at a wavelength of 562 nm, and
its absorbance was recorded as A1. The blank multiple emul-
sions without nattokinase were treated similarly and regarded
as a control, and its absorbance was recorded as A0, then the
absorbance of nattokinase which leaked into the outer aqueous
phase was recorded as A2 = A1–A0, the concentration C2 of
nattokinase in the outer aqueous phase was calculated ac-
cording to the standard curve equation y = 1.1541× + 0.0968,
R2 = 0.9992. The yield of nattokinase-loaded SDEDDS was
determined according to the formula (2). Analyses for each
formulation were carried out in triplicate, and data were
presented as Mean ± SD.
Yield %( ) = − ×W W
W
1 2
1
100 (2)
where W1 is the original amount of nattokinase incorporated
into the internal aqueous phase, W2 is the amount nattokinase
leaked into the outer aqueous phase at a given time t, it was
calculated according to the formula W2 = C2V2, where V2 is the
volume of outer aqueous phase.
The stability of freshly prepared SDEDDS formulations and
after 30 d storage at room temperature was compared by moni-
toring the time-dependent changes in terms of microscopic
morphology, oil droplet size, yield and so on. The leakage rates
of the emulsions after storage may reflect the encapsulation
stability, which can be defined as the percentage of the water-
soluble drug added to the inner aqueous phase which remains
entrapped in the inner aqueous phase following storage [22].
2.3.6. In vitro drug release study
The release of nattokinase from SDEDDS formulations in vitro
was investigated on a dissolution apparatus ZRS-8G, Tian Da
Tian Fa Technology Company (Tianjin, China). Briefly, appro-
priate amounts of blank and nattokinase-loaded SDEDDS
formulations were separately added into the dissolution vessels
containing 100 ml of different release media, such as water,
phosphate buffer solution (pH 6.80), hydrochloric acid solu-
tion (pH 1.21) and acetic acid-sodium acetate buffer (pH 4.50).
Taking into account the thermal instability of nattokinase, the
temperature of the release medium was maintained at
25 ± 0.5 °C, and the speed of the paddle was adjusted to 100 rpm.
Subsequently, 2 ml sample was withdrawn and immediately
replaced by fresh medium at fixed time intervals (5, 15, 30, 45,
60, 90, 120, 180, 240, 360 and 480 min). The cumulative release
of nattokinase from SDEDDS formulations was determined, and
then the release profiles were drawn. Analyses for each for-
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mulation were carried out in triplicate, and data were presented
as Mean ± SD.
2.3.7. Pharmacodynamics study of nattokinase-loaded
SDEDDS formulations
2.3.7.1. Influence of different prescription groups on whole blood
clotting time of mouse. A total of 70 KM mice were randomly
divided into seven groups as follows: normal saline control
group; low- (8630 FU/kg.bw), medium- (12,945 FU/kg.bw) and
high-dose (17,260FU/kg.bw) nattokinase solution groups; low-
(8630 FU/kg.bw), medium- (12,945 FU/kg.bw) and high-dose
(17,260FU/kg.bw) nattokinase-loaded SDEDDS formulation
groups. Mice were daily fed by gavage for 14 days (n = 10) and
anesthetized with ether at 1 h after last intragastric admin-
istration. A drop of blood was collected from the eye ground
vein onto the glass slide by a 0.5-mm capillary glass tube. The
blood drop was immediately and gently provoked from the edge
to the center with clean needles at regular intervals until the
bloodshot was observed. This period was considered as the
whole blood clotting time of mouse in vitro.
2.3.7.2. Influence of different prescription groups on tail throm-
bosis of mouse. Animals were grouped and administrated as
same as in section 2.3.7.1. Briefly, 2 h after last intragastric ad-
ministration, mice were administered with 0.5% carrageenan
(w/v) at a dose of 0.1 ml/10 g by peritoneal injection to induce
tail thrombosis. The length of tail thrombus was determined
at 8 h, 24 h and 48 h, and then the relative length of tail throm-
bus was calculated according to the formula (3).
Fig. 1 – Pseudo-ternary phase diagram of (w/o)/labrasol/water showing double emulsion region. (Data shown as Mean ± SD,
n = 3).
Table 1 – Results of self-emulsifying area of different SDEDDS formulations.
Number Oil phase Lipophilic emulsifier Hydrophilic emulsifier Self-emulsifying
area (%)
A MCT Span80 Labrasol 18.5
B MCT Arlacel P135 Labrasol 26.2
C MCT EM90 Labrasol 41.8
D liquid paraffin EM90 Labrasol 23.6
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Thrombosis relative length
tail thrombus length
the full
%( ) =
 tail length
× 100(3)
2.3.7.3. Statistical analysis. Data were presented as Mean ± SD
(n = 10). Statistical significance of differences among groups
was performed by one-way ANOVA and Kruskal-Walis H test,
and then the statistical significance of the means was deter-
mined by SNK or Dunnett-t test. A P value of less than 0.05
was considered as statistically significant.
3. Results and discussions
3.1. Screening the composition and preparation condition
of SDEDDS formulations
Fig. 1 shows pseudo-ternary phase diagrams of four prescrip-
tions shown in Table 1.The shaded area indicates that SDEDDS
formulations could self-emulsify into water/oil/water mul-
tiple emulsions. By comparing the self-emulsifying area, we
could conclude that MCT had a better emulsifying capacity than
liquid paraffin; and EM90 had a better emulsifying capacity than
Arlacel P135 and Span 80. The maximum self-emulsifying area
of the prescription C was 41.8%. Then we optimized the con-
centrations of emulsifier and inner aqueous phase using MCT
and Abil EM90 as oil phase and lipophilic emulsifier, respectively.
Fig. 2A shows that the oil globule sizes of water/oil/water
multiple emulsions were decreased when the concentration
of hydrophilic emulsifier was increased from 10% to 15% (w/
w) with a constant concentration of EM90. However, when the
concentration of the hydrophilic emulsifier reached 20% (data
not shown), most droplets of water/oil/water emulsions oc-
curred in phase inversion. It seemed that excess of hydrophilic
emulsifier destabilized the multiple emulsions. This could be
caused by that the excess of hydrophilic emulsifier formed
mixed micelles, which could dissolve the oil phase and lipo-
philic emulsifier, leading to film rupture and accelerated release
of drugs in inner aqueous phase. Therefore, the yield of for-
mulations was also reduced [23,24]. Moreover, the oil globule
sizes of water/oil/water emulsions were increased with the in-
crease of inner aqueous phase. This could be explained by that
increased inner aqueous phase resulted in the high viscosity
of the water/oil emulsions, leading to hard dispersion of the
SDEDDS formulations into the outer aqueous phase to form
water/oil/water multiple emulsions.Therefore, droplets of water/
oil/water emulsions with larger size finally formed [25]. In
addition, the oil globule sizes of water/oil/water emulsions were
decreased when the lipophilic emulsifier concentration was in-
creased from 10% to 20% with a constant concentration of
Labrasol. However, the oil globule sizes were increased when
the lipophilic emulsifier concentration was greater than 25%
(Fig. 2B). This could be explained by that the water-oil inter-
facial tension was reduced with the increase of the lipophilic
emulsifier concentration from 10% to 20%, resulting in the
reduced sizes of oil droplets. However, the lipophilic emulsi-
fier was saturated in the water-oil interface at a concentration
above 25% [26], and the interfacial tension was no longer
reduced. On the contrary, the viscosity of water/oil emul-
sions was too large, leading to hard dispersion of SDEDDS [23].
Comprehensively considering the morphology, particle size
and self-emulsifying area of water/oil/water multiple emul-
sions transformed from SDEDDS formulations, we found that
MCT was the oil phase, Abil EM90 was the lipophilic emulsi-
fier and Labrasol was the hydrophilic emulsifier in the optimum
SDEDDS formulations. In addition, the optimum concentra-
tion of Abil EM90, Labrasol and inner aqueous phase was 20%
(w/w), 15% (w/w) and 40% (w/w), respectively.
Table 2 shows that the oil globule sizes of water/oil/water
multiple emulsions were slightly increased with the homog-
enization time increasing at a constant 10,000 rpm or
Fig. 2 – The oil globule size of w/o/w multiple emulsions transformed from SDEDDS formulations changes with various
concentration of inner water phase and hydrophilic emulsifier (A), lipophilic emulsifier (B). (Data shown as Mean ± SD,
n = 3).
Table 2 – Results of oil globule sizes of water/oil/water
multiple emulsions under different homogenization
condition for preparing the w/o emulsions.
Homogenization
strength (rpm)
Homogenization
time (min)
D[4,3] (μm)
Mean ± SD
10,000 3 4.83 ± 0.24
6 5.25 ± 0.18
9 5.45 ± 0.30
13,000 3 4.65 ± 0.45
6 5.37 ± 0.37
9 6.85 ± 0.29
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13,000 rpm. In the end, we determined the best w/o prepara-
tion condition was 10,000 rpm 3 min, at the moment the water/
oil/water multiple emulsions owned relatively small volume-
weighted mean droplet size and good morphology.
3.2. Characterization of SDEDDS formulations
3.2.1. Microscopic structure observation
Fig. 3A–C show that the freshly prepared optimum SDEDDS for-
mulations could self-emulsify into fine water/oil/water multiple
emulsions after dilution with water (37 ± 0.5 °C) under gentle
stirring. The structure analysis revealed that the dispersed oil
droplets contained smaller dispersed inner water droplets,
which was in accordance with the characteristics of multiple
emulsions [25,27,28].
3.2.2. Particle size analysis
Fig. 3D shows the microstructure of inner water droplets of mul-
tiple emulsions, the average particle size of water/oil emulsions
was about 580 ± 20 nm, and the particle size of water/oil emul-
sions was distributed in a range of 250–800 nm.
Fig. 4 reveals that the oil droplet size of water/oil/water mul-
tiple emulsions transformed from SDEDDS formulations was
6.0 ± 0.7 μm, representing a typical bimodal distribution of mul-
tiple emulsions. This could be explained by that the small size
internal water droplets promoted the formation of larger oil
droplets, thereby forming the second globule peak which be-
longed to the bimodal oil droplet distribution [29–31]. The
polydispersity of the oil droplet size distribution was ex-
pressed as span [23], which was defined as follows:
span
D D
D
=
( ) − ( )
( )
0 9 0 1
0 5
, ,
,
(4)
where D (0, 5) is the size in microns at which 50% of the sample
is larger and 50% is smaller; D (0, 1) and D (0, 9) are the sizes
of the droplets below 10% and 90%, respectively, of the sample
lies. The span of the oil droplet size of water/oil/water emul-
sions transformed from SDEDDS formulations was 1.7 ± 0.2.
3.2.3. Determination of the self-emulsifying rate of SDEDDS
formulations
The self-emulsifying rate of SDEDDS formulations reflects the
self-emulsifying ability [32]. The faster self-emulsifying rate,
the better self-emulsifying ability of SDEDDS formulations,
and vice versa. Experimental results indicated that as the
Fig. 3 – Microscopy images (A × 400), Oil microscopey images (B × 1000), Confocal microscopy images (C × 2000),
Transmission electron microscopey images (D × 20000) of freshly prepared nattokinase-SDEDDS formulations transformed
into fine w/o/w multiple emulsions after dilution with outer aqueous phase.
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hydrophilic emulsifier concentration was 10%, 15% and 20%,
the T90 was 2 min, 1.6 min and 1.5 min, respectively. T90 was
all less than 2 min, indicating that SDEDDS formulations had
high self-emulsifying ability. Fig. 5 exhibits the curves of tur-
bidity and relative turbidity of SDEDDS formulations versus time
when the hydrophilic emulsifier concentration was 15%.
3.2.4. Investigation of yield and storage stability
The initial yield of nattokinase-loaded SDEDDS formulations
was 86.8 ± 8.2%, whereas it was changed to 82.6 ± 9.1% after
stored at room temperature for 30 d. The morphology of
nattokinase-loaded SDEDDS formulations was barely changed.
Fig. 6 A–B show that the oil globule size was decreased from
5.3 ± 0.4 μm to 4.7 ± 0.7 μm for nattokinase-loaded SDEDDS
formulations and from 6.9 ± 0.4 μm to 3.4 ± 0.5 μm for blank
formulations. Data revealed that the nattokinase-loaded
SDEDDS formulations had smaller change in particle size,
showing better stability. This could be explained by that partial
proteins could be adsorbed at the oil/water interface, then in-
teract with the surfactants at the oil/water interface and
enhance the flexibility of the interfacial film. This process pre-
vented globule breaking, leading to the improved stability of
the emulsions [25].
3.2.5. In vitro drug release study
Fig. 7 shows the nattokinase release profiles from the optimum
SDEDDS formulations. The cumulative release of nattokinase
was about 30% after 8 h, providing a sustained release in four
different release media. We found that the SDEDDS formula-
tions were stable without an initial burst release due to the
release of poorly entrapped nattokinase [33]. In this study, the
cumulative release of nattokinase from SDEDDS formula-
tions was almost balanced within 8 h, which was consistent
with many studies. It has been reported that the cumulative
release of drugs from water/oil/water multiple emulsions in vitro
ranges from 20% to 40% within 10 h [34–36]. Especially for the
water/oil/water multiple emulsions containing Abil EM90 as
lipophilic emulsifier, their release is slow through the liquid
oil membrane (60% release after 30 days) [37]. We could also
control the drug release rate by adjusting the type and con-
centration of oil phase and emulsifier.
The rank order of nattokinase release rate in vitro was pH
1.21 > H2O > pH 4.50 > pH 6.80. In our previous study, we found
the rank order of oil droplet size of multiple emulsions in four
release media was pH 6.80 (5.47 ± 0.19 μm) > pH
4.50 (5.09 ± 0.20 μm) > H2O (4.83 ± 0.28 μm) > pH 1.21
(4.69 ± 0.32 μm). The reason may be that the smaller oil droplet
size, the larger interfacial area available for drug transport across
the oil phase barrier, then the faster drug release [30].
Table 3 shows that the release data fitted to Weibull equa-
tion since the highest correlation coefficients were obtained
(R2 from 0.97 to 0.99).
3.2.6. Pharmacodynamics study
Table 4 shows the results of whole blood clotting time in vitro.
We found that the whole blood clotting time was signifi-
cantly prolonged in low-, medium-, high-dose groups of
nattokinase-loaded SDEDDS formulations and high-dose group
Fig. 4 – Typical oil globule size distribution of freshly prepared nattokinase-SDEDDS formulations transformed into fine
w/o/w multiple emulsions after dilution with outer aqueous phase.
Fig. 5 – Curves of turbidity(A), relative turbidity(B) of SDEDDS after added into the outer aquous phase changing with time.
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of nattokinase solution compared with the normal saline control
group (P < 0.05). However, only a tendency of extended whole
blood clotting time was found in other groups compared with
the normal saline control group (P > 0.05). Carrageenan-
induced tail thrombosis model is used to evaluate
antithrombotic and thrombolytic agents. This model is simple
and non-invasive to the experimental animals. Moreover, it
allows observing and measuring progression of thrombosis con-
tinuously and accurately [38,39]. Table 4 shows that nattokinase-
loaded SDEDDS formulations could significantly improve mouse
tail thrombosis by reducing the mouse tail thrombosis average
relative length (P < 0.05). However, only a tendency of reduced
mouse tail thrombosis average relative length was detected in
nattokinase solution groups compared with the normal saline
control group (P > 0.05). In addition, the differences between
the high-dose group of nattokinase-loaded SDEDDS formula-
tions and the high-dose group of nattokinase solution were
statistically significant (P < 0.05), and the photos of mouse tail
thrombosis at 48 h were shown in Fig. 8. Therefore, we con-
cluded that the encapsulation of nattokinase in SDEDDS
formulations would better protect nattokinase against inac-
tivation in the stomach, leading to a better efficiency through
oral administration. Moreover, the efficacy of SDEDDS formu-
lations was also in a dose-dependent manner, and the best
efficacy was found in the high-dose group of nattokinase-
loaded SDEDDS formulations.
4. Conclution
In the present study, we successfully prepared the nattokinase-
loaded SDEDDS formulations. The optimal formulations were
Fig. 6 – Oil globule size distribution of fine w/o/w multiple emulsions transformed from blank SDEDDS(A), nattokinase–
loaded SDEDDS(B) after preparation immediately( ) and after 30 d storage period at room temperature ( ). (Data shown
as Mean ± SD, n = 3).
Fig. 7 – Release profiles of nattokinase from SDEDDS
formulations in four different release mediums. (Data
shown as Mean ± SD, n = 3).
Table 3 – Results of nattokinase release data simulated
by Weibull equation.
Release mediums Weibull equation R2
pH 1.21 F=32.455*{1−Exp[−((t+38.092)1.416/
266.251)]}
0.9894
pH 6.80 F=26.047*{1−Exp[−((t+10.124)0.591/
8.064)]}
0.9721
pH 4.50 F=27.210*{1−Exp[−((t+4.738)1.162/
99.246)]}
0.9839
H2O F=29.255*{1−Exp[−((t+16.174)0.96/
47.336)]}
0.9714
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still stable over a period of 30 d at room temperature.They could
self-emulsify into fine water/oil/water multiple emulsions upon
dilution in dispersion medium under gentle stirring, with small
volume-weighted mean droplet size, high yield and self-
emulsifying ability, and a sustained release of nattokinase
in vitro. Besides, in vivo pharmacodynamics results indicated
that the encapsulation of nattokinase in SDEDDS formula-
tions could better protect nattokinase against inactivation in
the stomach, leading to a better efficiency through oral ad-
ministration. Our findings suggested that SDEDDS could be a
promising strategy for peptide and protein drugs by oral
administration.
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